<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>95</volume><submitter>Delshad M</submitter><funding>Shahid Beheshti University of Medical Sciences</funding><pubmed_abstract>The incidence of the novel coronavirus disease (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought daunting complications for people as well as physicians around the world. An ever-increasing number of studies investigating the characteristics of the disease, day by day, is shedding light on a new feature of the virus with the hope that eventually these efforts lead to the proper treatment. SARS-CoV-2 activates antiviral immune responses, but in addition may overproduce pro-inflammatory cytokines, causing uncontrolled inflammatory responses in patients with severe COVID-19. This condition may lead to lymphopenia and lymphocyte dysfunction, which in turn, predispose patients to further infections, septic shock, and severe multiple organ</pubmed_abstract><journal>International immunopharmacology</journal><pagination>107586</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7969831</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.</pubmed_title><pmcid>PMC7969831</pmcid><pubmed_authors>Bashash D</pubmed_authors><pubmed_authors>Pourbagheri-Sigaroodi A</pubmed_authors><pubmed_authors>Delshad M</pubmed_authors><pubmed_authors>Tavakolinia N</pubmed_authors><pubmed_authors>Safaroghli-Azar A</pubmed_authors><pubmed_authors>Bagheri N</pubmed_authors></additional><is_claimable>false</is_claimable><name>The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.</name><description>The incidence of the novel coronavirus disease (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought daunting complications for people as well as physicians around the world. An ever-increasing number of studies investigating the characteristics of the disease, day by day, is shedding light on a new feature of the virus with the hope that eventually these efforts lead to the proper treatment. SARS-CoV-2 activates antiviral immune responses, but in addition may overproduce pro-inflammatory cytokines, causing uncontrolled inflammatory responses in patients with severe COVID-19. This condition may lead to lymphopenia and lymphocyte dysfunction, which in turn, predispose patients to further infections, septic shock, and severe multiple organ</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-19T17:59:32.265Z</modification><creation>2022-02-11T14:15:15.095Z</creation></dates><accession>S-EPMC7969831</accession><cross_references><pubmed>33765611</pubmed><doi>10.1016/j.intimp.2021.107586</doi></cross_references></HashMap>